AUPH News and Press, Aurinia Pharmaceuticals Inc From 03/24/23

2023-03-24 04:47:31 ET Summary Aurinia Pharmaceuticals' Lupkynis revenue figures aren't bad this quarter. However, the target population is the problem. I still think only a buyout from big pharma will unlock full potential. I covered Aurinia Pharmaceuticals ( ...

2023-03-24 00:53:15 ET Summary LUPKYNIS has had a lengthy and ultimately productive development pathway. Aurinia has gone all hands on deck to provide LUPKYNIS a successful launch. Forward earnings prospects are challenged by Aurinia's meager pipeline and by significant compet...

2023-03-23 15:56:20 ET Aurinia Pharmaceuticals ( NASDAQ: AUPH ) rose 6.5% amid renewed takeover speculation. There's speculation than unnamed suitor may be eyeing a takeover of Aurinia ( AUPH ), according to a Betaville "uncooked" alert, which cited people followin...

2023-03-23 06:22:38 ET Summary Aurinia Pharmaceuticals Inc. has strengthened its patent position in the industry and now has more clout as a marketer than just a developer of therapies. Its lead product, LUPKYNIS, an immunosuppressive drug for lupus nephritis, appears to be a high...

2023-03-21 17:57:26 ET Summary Despite positive results from the AURA-LV study, Lupkynis has not become the preferred LN treatment, leading to Aurinia's missed 2022 revenue projections. A study indirectly comparing drug regimens for LN induction therapy indicates tacrolimus plus M...

Aurinia Pharmaceuticals Inc. (AUPH) Q4 2022 Earnings Conference Call February 28, 2023 8:30 AM ET Company Participants Dana Lynch - Director of Corporate Communications & Corporate Affairs Peter Greenleaf - President & Chief Executive Officer Joe Miller - Chief...

Aurinia Pharmaceuticals ( NASDAQ: AUPH ) stock rose ~8% on Tuesday after Q4 net loss narrowed and revenue grew Y/Y. Net loss was -$26.05M, compared to -$33.32M in Q4 2021. Total net revenue grew +21.5% Y/Y to ~$28.44M, however it missed analysts estimates. Full year 2...

Aurinia Pharma press release ( NASDAQ: AUPH ): Q4 GAAP EPS of -$0.18 beats by $0.09 . Revenue of $28.4M (+21.4% Y/Y) misses by $0.42M . Cash, cash equivalents, and investments of $389.4 million as of December 31, 2022. For fiscal year 2023, the Company is reiterati...

$28.4 million in total net revenue for the fourth quarter 2022, a 21% increase over fourth quarter 2021 and $134.0 million for full year 2022, a 194% increase over 2021 Cash, cash equivalents, and investments of $389.4 million as of December 31, 2022 Conference call to be hosted t...

Aurinia Pharma ( NASDAQ: AUPH ) is scheduled to announce Q4 earnings results on Tuesday, February 28th, before market open. The consensus EPS Estimate is -$0.27 (vs. -$0.25 last year) and the consensus Revenue Estimate is $28.82M (+23.2% Y/Y). Over the last 1 year, AUPH ...